PCV5 DEVELOPMENT OF TESTS FOR EARLY DIAGNOSIS OF PREECLAMPSIA
Schiff L 1 , Foster T 1 , Creeden J 2 , van der Helm W 2 , Gartemann J 2 , Pashos CL 1 1 Abt Bio-Pharma Solutions, Inc., Lexington, MA, USA, 2 Roche Diagnostics, Ltd, Rotkreuz, Switzerland OBJECTIVES: Preeclampsia complicates 5-8% of all pregnancies and remains a leading cause of maternal and perinatal morbidity and mortality. Negative outcomes could be avoided in many patients if a reliable early diagnostic test were available. We systematically reviewed the literature to assess the current status of development of early diagnostic tests for preeclampsia. METHODS: We searched English-language MEDLINE-indexed publications in the 10 years prior to August 2008 concerning tests for early diagnosis of preeclampsia, and literature published in the 5 years prior to August 2008 using keywords relating to biomarkers for preeclampsia. We also searched non-MEDLINE-indexed sources such as organization websites, meeting abstracts, and governmental publications using the same keywords. RESULTS: We identifi ed 116 primary studies from MEDLINE pertaining to biomarkers or tests for early diagnosis of preeclampsia. Non-MEDLINE sources yielded an additional 2 articles for a total of 118 reviewed for this study. A variety of serum biomarkers have been explored as candidates for predictive diagnostic tests for preeclampsia. These biomarkers represent a number of pathological processes involved in preeclampsia, including endothelial damage, oxidative stress, altered lipid and glucose metabolism, infl ammation, and abnormal immune responses. The angiogenesis-related biomarkers PlGF and sFlt-1 are at the most advanced state of development as diagnostic tests, with PlGF decreases and sFlt-1 increases preceding overt clinical symptoms by 5-10 weeks. PlGF has potential to allow screening as early as 14 weeks of gestation, and sFlt-1 by week 16. Further research is needed to determine whether change in these biomarkers predicts preeclampsia or indicates substantially increased risk, or conversely, whether lack of change precludes preeclampsia or indicates lower risk. CON-CLUSIONS: Currently, the angiogenesis-related biomarkers PlGF and sFlt-1 offer the most promise for use in the early diagnosis of preeclampsia.
PCV6 BURDEN OF HYPERLIPIDEMIA AND ASSOCIATED TREATMENT PATTERNS IN EUROPE: A COMPARISON OF FIVE COUNTRIES
Narayanan S y 1 , Potthoff P 2 , Guether B 2 1 TNS Healthcare, New York, NY, USA, 2 TNS Healthcare, Munich, Bavaria, Germany OBJECTIVES: To assess burden of hyperlipidemia and associated treatment patterns among fi ve European nations. METHODS: European Healthcare Panel of over 160,000 individuals in France, Germany, Italy, UK and the Netherlands were surveyed in 2007 to assess disease burden at national level, to build an epidemiological database in these 5 countries. The data is representative of population gender and age (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) (36) (37) (38) (39) (40) (41) (42) (43) (44) (45) (46) (47) (48) (49) (50) (51) (52) (53) (54) (55) (56) (57) (58) (59) (60) (61) (62) (63) (64) 65 -69 yrs) strata in respective countries, ensured by sampling and intensive panel management. The survey collected information on select health conditions (incl. hyperlipidemia, in terms of high cholesterol; in the past 12-months), quality of life and health care-utilization. RESULTS: Prevalence of Hyperlipidemia varied widely between the 5 nations, as follows: Italy: 10.7%, the Netherlands: 11.2%, U.K: 12.4%, France: 14.8%, Germany: 15.5%. Within each country, burden of hyperlipidemia varied by age and gender; distribution among male (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) (36) (37) (38) (39) (40) (41) (42) (43) (44) (45) (46) (47) (48) (49) (50) (51) (52) (53) (54) (55) (56) (57) (58) (59) (60) (61) (62) (63) (64) 65 13.71%,Not-Medically-Diagnosed:5.4%; Germany: GP-76.1%,Specialist:16.0%, Hospital:5.3%,Not-Medically-Diagnosed:2.6%; U.K: GP-79.0%,Specialist:6.6%, Hospital:11.4%,Not-Medically-Diagnosed:3.0%; France: GP-83.3%,Specialist:9.2%, Hospital:5.0%,Not-Medically-Diagnosed:2.6%. Majority were treated by their GPs (range: 47.6% (Italy) to 72.4% (U.K)), followed by Specialists (range: 3.6% (U.K) to 20.1% (the Netherlands)). Being currently not medically treated was reported by 15.0%,15.7%,19.7%,20.0%,25.7% of individuals in Italy/U.K/France/the Netherlands/Germany respectively. Use of prescription medications predominated, while prescription cost-reimbursement varied in the following order: fully-recompensated (range: 18.3% (Germany) to 69.9% (UK)), with-co-payment (range: 0.0% (UK) to 27.3% (Germany)) and complete-Out-of-Pocket (range: 0.0% (UK) to 12.1% (France)). OTC product use very low (range: 0.8% (France) to 3.1% (Italy)). CONCLUSIONS: Hyperlipidemia disease burden appear to be substantial and increased with age. Treatment patterns and prescription cost reimbursement scenarios were diverse across the fi ve European nations, with a sizable proportion remaining medically untreated.
PCV7 BURDEN OF HYPERTENSION AND ASSOCIATED TREATMENT PATTERNS IN EUROPE: A COMPARISON OF FIVE COUNTRIES
Narayanan S y 1 , Potthoff P 2 , Guether B 2 1 TNS Healthcare, New York, NY, USA, 2 TNS Healthcare, Munich, Bavaria, Germany OBJECTIVES: To assess hypertension disease burden and associated treatment patterns among fi ve European nations. METHODS: A large multi-country online cross-sectional survey of over 160,000 adults was conducted in 2007 in France, Germany, Italy, UK and the Netherlands by TNS Healthcare. The survey enabled TNS to build an epidemiological database based on its proprietary European Healthcare Panel (EHP) of consumers in these 6 countries. The data is representative of population gender and age (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) (36) (37) (38) (39) (40) (41) (42) (43) (44) (45) (46) (47) (48) (49) (50) (51) (52) (53) (54) (55) (56) (57) (58) (59) (60) (61) (62) (63) (64) 65 -69 yrs) strata in respective countries, ensured by sampling and intensive panel management. The survey collected information on select health conditions (incl. hypertension; in the past 12-months), quality of life and health care-utilization. RESULTS: Hypertension disease prevalence varied widely between the 5 nations, as follows: France: 15.0%, Netherlands: 15.6%, U.K: 17.6%, Italy: 18.6%, Germany: 19.8%. Within each country, burden of hypertension increased with age, among both males and females; distribution among male (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) (36) (37) (38) (39) (40) (41) (42) (43) (44) (45) (46) (47) (48) (49) (50) (51) (52) (53) (54) (55) (56) (57) (58) (59) (60) (61) (62) (63) (64) 65 yrs: % pts) was: France: 5.2%,6.0%,8.6%,18.6%,31.8%,36.4; the Netherlands: 1.3%,2.0%,9.3%,19.5%, 32.8%,36.0; U.K: 3.5%,5.9%,12.0%,22.8%,37.7%,43.6; Italy: 5.5%,5.8%,13.3%, 27.7%38.7%,43.6%; Germany: 7.0%,7.8%,14.4%,26.3%,38.3%,44.0%; distribution among female (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) (36) (37) (38) (39) (40) (41) (42) (43) (44) (45) (46) (47) (48) (49) (50) (51) (52) (53) (54) (55) (56) (57) (58) (59) (60) (61) (62) (63) (64) 65 yrs: % pts) was: France: 5.5%,6.1%,8.5%,17.7%,27.8%,32.8%; the Netherlands: 2.0%,7.1%,10.9%,21.2%, 28.4%,34.8%; U.K: 5. 0%, 5.8%, 9.6%, 19.3%, 29.2%, 40.6%; Italy: 3.7%, 4.0%, 8.3%, 20.4%, 28.6%, 48.5%; Germany: 4.7%, 5.3%, 11.2%, 22.7%, 32.7%, 37 .7%. Point of diagnosis varied across the countries: Italy: GP-43.0%,Specialist:34.1%, Hospital:17.7%,Not-Medically-Diagnosed:5.0%; Germany: GP-67.6%,Specialist: 22.3%,Hospital:6.1%,Not-Medically-Diagnosed:3.9%; Netherland: GP-69.8%,Specialist:17.2%,Hospital:8.6%,Not-Medically-Diagnosed:6.2%; France: GP-77.76%, Specialist:12.7%,Hospital:5.9%,Not-Medically-Diagnosed:3.7%; U.K: GP-83.6%, Specialist:4.8%,Hospital:7.9%,Not-Medically-Diagnosed:3.6%. Individuals were primarily treated by their GPs (range: 49.4% (Italy) to 77.2% (U.K)), followed by Specialists (range: 2.8% (U.K) to 26.8% (Italy)). Being currently not medically treated was reported by 10.8%,11.6%,13.0%,15.1%,16.0% of individuals in Italy/ Germany/ France/U.K/Netherlands respectively. Use of prescription medications predominated, while prescription cost-reimbursement varied: fully-recompensatedrange: 31.0% (Germany) to 78.8% (Italy), with-co-payment-range: 0.0% (U.K) to 51.1% (Germany) and complete-Out-of-Pocket-range: 0.0% (U.K) to 14.8% (France). CONCLUSIONS: Hypertension disease burden appear to be substantial and increased with age, accompanied by diverse treatment patterns and prescription cost reimbursement scenarios across the fi ve European nations.
